Leon A Bach

List of Publications by Year
in descending order

112 papers	4,064 citations	117453 34 h-index	128067 60 g-index
112 all docs	112 docs citations	112 times ranked	4672 citing authors

#	Article	IF	Citations
1	Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). Journal of Clinical Investigation, 2001, 108, 1853-1863.	3.9	397
2	Inhibition of NADPH Oxidase Prevents Advanced Glycation End Productâ€“Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-Î±â€“Dependent Pathway. Diabetes, 2008, 57, 460-469.	0.3	317
3	IGF-binding proteins â€“ the pieces are falling into place. Trends in Endocrinology and Metabolism, 2005, 16, 228-234.	3.1	153
4	Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-Â-Dependent Pathway. Diabetes, 2004, 53, 2921-2930.	0.3	149
5	Endothelial cells and the IGF system. Journal of Molecular Endocrinology, 2015, 54, R1-R13.	1.1	139
6	IGFBP-6 five years on; not so â€˜forgottenâ€™?. Growth Hormone and IGF Research, 2005, 15, 185-192.	0.5	100
7	Insulinâ€like growth factors and diabetes. Diabetes/metabolism Reviews, 1992, 8, 229-257.	0.2	98
8	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020, 43, 3024-3033.	4.3	85
9	Insulin-like Growth Factors and Kidney Disease. American Journal of Kidney Diseases, 2015, 65, 327-336.	2.1	84
10	Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2016, 18, 772-783.	2.4	77
11	Dexamethasone and Surgical-Site Infection. New England Journal of Medicine, 2021, 384, 1731-1741.	13.9	76
12	SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3077-3087.	1.8	74
13	Effect of Puberty on Initial Kidney Growth and Rise in Kidney IGF-I in Diabetic Rats. Diabetes, 1990, 39, 557-562.	0.3	71
14	Human insulin-like growth factor binding protein-6 is O-glycosylated. Biochemical and Biophysical Research Communications, 1992, 186, 301-307.	1.0	69
15	Diabetes Is a Major Risk Factor for Mortality After Lung Transplantation. American Journal of Transplantation, 2014, 14, 438-445.	2.6	68
16	The high burden of inpatient diabetes mellitus: the Melbourne Public Hospitals Diabetes Inpatient Audit. Medical Journal of Australia, 2014, 201, 334-338.	0.8	65
17	Identification of O-Glycosylation Sites and Partial Characterization of Carbohydrate Structure and Disulfide Linkages of Human Insulin-like Growth Factor Binding Protein 6â€. Biochemistry, 1998, 37, 6572-6585.	1.2	64
18	The N-terminal Disulfide Linkages of Human Insulin-like Growth Factor-binding Protein-6 (hIGFBP-6) and hIGFBP-1 Are Different as Determined by Mass Spectrometry. Journal of Biological Chemistry, 1999, 274, 14587-14594.	1.6	64

#	Article	IF	Citations
19	Insulin-like growth factor-binding protein-6 and cancer. Clinical Science, 2013, 124, 215-229.	1.8	63
20	Papillary thyroid cancerâ€“derived exosomes contain miRNA-146b and miRNA-222. Journal of Surgical Research, 2015, 196, 39-48.	0.8	63
21	Promotion of Cancer Cell Migration. Journal of Biological Chemistry, 2007, 282, 22298-22306.	1.6	59
22	Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growthin vivo. International Journal of Cancer, 2001, 94, 645-651.	2.3	58
23	The Amino-terminal Domains of the Ezrin, Radixin, and Moesin (ERM) Proteins Bind Advanced Glycation End Products, an Interaction That May Play a Role in the Development of Diabetic Complications. Journal of Biological Chemistry, 2003, 278, 25783-25789.	1.6	56
24	Recent insights into the actions of IGFBP-6. Journal of Cell Communication and Signaling, 2015, 9, 189-200.	1.8	53
25	Inhibition of Plasmodium falciparum CDPK1 by conditional expression of its J-domain demonstrates a key role in schizont development. Biochemical Journal, 2013, 452, 433-441.	1.7	51
26	Structure, Dynamics and Heparin Binding of the C-terminal Domain of Insulin-like Growth Factor-binding Protein-2 (IGFBP-2). Journal of Molecular Biology, 2006, 364, 690-704.	2.0	50
27	IGF binding proteinâ€6 expression in vascular endothelial cells is induced by hypoxia and plays a negative role in tumor angiogenesis. International Journal of Cancer, 2012, 130, 2003-2012.	2.3	50
28	O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. FEBS Journal, 2000, 267, 5378-5386.	0.2	47
29	Prohibitin-2 Binding Modulates Insulin-like Growth Factor-binding Protein-6 (IGFBP-6)-induced Rhabdomyosarcoma Cell Migration. Journal of Biological Chemistry, 2013, 288, 29890-29900.	1.6	47
30	Several Acidic Amino Acids in the N-domain of Insulin-like Growth Factor-binding Protein-5 Are Important for Its Transactivation Activity*. Journal of Biological Chemistry, 2006, 281, 14184-14191.	1.6	46
31	C-Terminal Domain of Insulin-Like Growth Factor (IGF) Binding Protein-6: Structure and Interaction with IGF-II. Molecular Endocrinology, 2004, 18, 2740-2750.	3.7	44
32	Inhibition of Caco-2 cell proliferation by all-trans retinoic acid: Role of insulin-like growth factor binding protein-6. Journal of Cellular Physiology, 2002, 190, 92-100.	2.0	43
33	Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Molecular and Cellular Endocrinology, 2001, 174, 121-127.	1.6	42
34	What Happened to the IGF Binding Proteins?. Endocrinology, 2018, 159, 570-578.	1.4	36
35	Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. Journal of Cellular Physiology, 2003, 197, 131-138.	2.0	35
36	Insulin-like growth factor binding protein-6 (IGFBP-6) interacts with DNA-end binding protein Ku80 to regulate cell fate. Cellular Signalling, 2010, 22, 1033-1043.	1.7	35

#	Article	IF	Citations
37	IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1511-1519.	1.8	35
38	Prevalence and Predictors of Diabetes After Lung Transplantation: A Prospective, Longitudinal Study. Diabetes Care, 2014, 37, 2919-2925.	4.3	35
39	Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding. Journal of Molecular Endocrinology, 2004, 33, 377-386.	1.1	34
40	Outcomes for general medical inpatients with diabetes mellitus and new hyperglycaemia. Medical Journal of Australia, 2008, 188, 340-343.	0.8	34
41	Localization of mRNAs for insulin-like growth factor binding proteins 1 to 6 in rat kidney. Kidney International, 1995, 48, 402-411.	2.6	32
42	Targeting the <scp>AGEâ€RAGE</scp> axis improves renal function in the context of a healthy diet low in advanced glycation endâ€product content. Nephrology, 2013, 18, 47-56.	0.7	30
43	Current ideas on the biology of IGFBP-6: More than an IGF-II inhibitor?. Growth Hormone and IGF Research, 2016, 30-31, 81-86.	0.5	29
44	Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients. Transplantation, 2017, 101, 2200-2206.	0.5	29
45	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. Contemporary Clinical Trials, 2020, 90, 105892.	0.8	29
46	â€œIt Is Definitely a Game Changerâ€: A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 410-416.	2.4	28
47	Cooperativity of the N- and C-Terminal Domains of Insulin-like Growth Factor (IGF) Binding Protein 2 in IGF Binding. Biochemistry, 2007, 46, 13720-13732.	1.2	26
48	Insulin-like growth factor binding proteins 4-6. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 713-722.	2.2	26
49	Induction of insulinâ€like growth factor binding protein expression by ICI 182,780 in a tamoxifenâ€resistant human breast cancer cell line. Breast Cancer Research and Treatment, 1999, 55, 231-242.	1.1	25
50	Inhibition of CACO-2 cell proliferation by (n-3) fatty acids: possible mediation by increased secretion of insulin-like growth factor binding protein-6. Nutrition Research, 2000, 20, 1409-1421.	1.3	24
51	Localization of the Insulin-like Growth Factor System in a Rat Model of Heart Failure Induced by Myocardial Infarction. Journal of Histochemistry and Cytochemistry, 1999, 47, 649-659.	1.3	23
52	Crossâ€talk between MAP kinase pathways is involved in IGFâ€independent, IGFBPâ€6â€induced Rh30 rhabdomyosarcoma cell migration. Journal of Cellular Physiology, 2010, 224, 636-643.	2.0	23
53	Rho Kinase Inhibition: A New Approach for Treating Diabetic Nephropathy?. Diabetes, 2008, 57, 532-533.	0.3	22
54	Binding site for the C-domain of insulin-like growth factor (IGF) binding protein-6 on IGF-II; implications for inhibition of IGF actions. FEBS Letters, 2004, 568, 19-22.	1.3	21

#	Article	IF	Citations
55	Preservation of Kidney Function with Combined Inhibition of NADPH Oxidase and Angiotensin-Converting Enzyme in Diabetic Nephropathy. American Journal of Nephrology, 2010, 32, 73-82.	1.4	21
56	Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of IGFBP6. Oncotarget, 2017, 8, 60826-60840.	0.8	21
57	The N-Terminal Subdomain of Insulin-like Growth Factor (IGF) Binding Protein 6. Structure and Interaction with IGFsâ€. Biochemistry, 2007, 46, 3065-3074.	1.2	20
58	Stereotactic radiosurgery for treatment of <scp>C</scp>ushing disease: an <scp>A</scp>ustralian experience. Internal Medicine Journal, 2012, 42, 1153-1156.	0.5	20
59	Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrology Dialysis Transplantation, 2000, 15, 347-354.	0.4	19
60	Insulin-like growth factors induce apoptosis as well as proliferation in LIM 1215 colon cancer cells. Journal of Cellular Biochemistry, 2007, 100, 58-68.	1.2	19
61	Expression of the IGF System in Normal and Diabetic Transgenic (mRen-2)27 Rat Eye. , 2005, 46, 2708.		18
62	Differential Effects of Insulin-Like Growth Factor Binding Protein-6 (IGFBP-6) on Migration of Two Ovarian Cancer Cell Lines. Frontiers in Endocrinology, 2015, 5, 231.	1.5	18
63	The insulin-like growth factor system: towards clinical applications. Clinical Biochemist Reviews, 2004, 25, 155-64.	3.3	18
64	Differential dissociation kinetics explain the binding preference of insulin-like growth factor binding protein-6 for insulin-like growth factor-II over insulin-like growth factor-I. FEBS Letters, 1999, 450, 240-244.	1.3	17
65	Advanced Glycation End Products Inhibit Tubulogenesis and Migration of Kidney Epithelial Cells in an Ezrin-Dependent Manner. Journal of the American Society of Nephrology: JASN, 2006, 17, 414-421.	3.0	17
66	Blogging During Terminal Care: Communication, Color Schemes, and Creating a Community. Journal of Clinical Oncology, 2008, 26, 4504-4506.	0.8	17
67	Advanced glycation end products inhibit Na+ K+ ATPase in proximal tubule epithelial cells: Role of cytosolic phospholipase A2Î± and phosphatidylinositol 4-phosphate 5-kinase Î³. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 919-930.	1.9	17
68	Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1). Diabetes, 2018, 67, 755-768.	0.3	17
69	C-Terminal Domain of Insulin-like Growth Factor (IGF) Binding Protein 6:Â Conformational Exchange and Its Correlation with IGF-II Bindingâ€. Biochemistry, 2004, 43, 11187-11195.	1.2	16
70	Uptake of advanced glycation end products by proximal tubule epithelial cells via macropinocytosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2922-2932.	1.9	15
71	Glomerular filtration rate in early experimental diabetes. The Journal of Diabetic Complications, 1988, 2, 8-11.	0.2	14
72	A case of mucormycosis limited to the parotid gland. Head and Neck, 2005, 27, 1108-1111.	0.9	14

#	Article	IF	Citations
73	Advanced glycation endâ€products induce calpainâ€mediated degradation of ezrin. FEBS Journal, 2012, 279, 3240-3250.	2.2	14
74	The insulin-like growth factor system in kidney disease and hypertension. Current Opinion in Nephrology and Hypertension, 2012, 21, 86-91.	1.0	13
75	Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitorâ€“Treated Type 2 Diabetes. Diabetes Care, 2021, 44, e124-e126.	4.3	11
76	HaCaT human keratinocytes express IGF-II, IGFBP-6, and an acid-activated protease with activity against IGFBP-6. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E536-E542.	1.8	9
77	An unexpectedly high prevalence of undiagnosed diabetes in patients awaiting lung transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 86-91.	0.3	9
78	Myopathy secondary to empagliflozin therapy in type 2 diabetes. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	9
79	Diabetes-related renal growth and IGF-I accumulation in castrated rats. Diabetes Research and Clinical Practice, 1991, 14, 15-20.	1.1	8
80	Prediction of persistent microalbuminuria in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 1993, 7, 67-72.	1.2	8
81	Prevention of apoptosis by insulin-like growth factor (IGF)-I and IGF-II is differentially attenuated by IGF-binding proteins in PC12 cells. Neuroscience Research Communications, 2000, 27, 75-83.	0.2	8
82	Association of a Nicotinic Receptor Mutation with Reduced Height and Blunted Physostigmine-Stimulated Growth Hormone Release. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 634-637.	1.8	8
83	The perioperative administration of dexamethasone and infection (PADDI) trial protocol: rationale and design of a pragmatic multicentre non-inferiority study. BMJ Open, 2019, 9, e030402.	0.8	8
84	Clinical, psychological and demographic factors in a contemporary adult cohort with diabetic ketoacidosis and type 1 diabetes. Internal Medicine Journal, 2021, 51, 1292-1297.	0.5	7
85	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 2021, 23, 460-466.	2.4	7
86	Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018, 8, e020274.	0.8	7
87	Response to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitorâ€“Treated Type 2 Diabetes. Diabetes Care 2021;44:e124â€“e126. Diabetes Care, 2022, 45, e17-e18.	4.3	7
88	Effect of an Insulin-Like Growth Factor Binding Protein Fusion Protein on Thymidine Incorporation in Neuroblastoma and Rhabdomyosarcoma Cell Lines. Endocrinology, 2004, 145, 3369-3374.	1.4	6
89	Localization of the ezrin binding epitope for advanced glycation endproducts. International Journal of Biochemistry and Cell Biology, 2008, 40, 1570-1580.	1.2	6
90	Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products. Nephrology, 2016, 21, 13-20.	0.7	6

#	Article	IF	Citations
91	Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence. Growth Hormone and IGF Research, 2018, 39, 6-12.	0.5	6
92	Hypertension and Cardiac Hypertrophy in Growth Hormone-Deficient Rats. Clinical Science, 1994, 87, 239-243.	1.8	5
93	1H, 13C and 15N resonance assignments of the C-terminal domain of insulin-like growth factor binding protein-6 (IGFBP-6). Journal of Biomolecular NMR, 2003, 25, 251-252.	1.6	5
94	Localization of the Ezrin Binding Epitope for Glycated Proteins. Annals of the New York Academy of Sciences, 2005, 1043, 617-624.	1.8	5
95	Effects of Advanced Glycation End Products on Ezrin-Dependent Functions in LLC-PK1 Proximal Tubule Cells. Annals of the New York Academy of Sciences, 2005, 1043, 609-616.	1.8	5
96	Prevalence of hyperglycaemia without previously recognised diabetes mellitus in the emergency department and subsequent management: a retrospective crossâ€sectional study. Internal Medicine Journal, 2020, 50, 1397-1403.	0.5	5
97	Demographics and outcomes of inpatients with diabetic foot ulcers treated conservatively and surgically in a metropolitan hospital network. Diabetes Research and Clinical Practice, 2021, 175, 108821.	1.1	5
98	Palpation thyroiditis following subtotal parathyroidectomy for hyperparathyroidism. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.2	5
99	Towards Identification of a Binding Site on Insulin-Like Growth Factor-II for IGF-Binding Proteins. Advances in Experimental Medicine and Biology, 1994, 343, 55-61.	0.8	4
100	Sodiumâ€“glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. Medical Journal of Australia, 2020, 212, 294.	0.8	3
101	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 2021, 179, 109000.	1.1	3
102	Insulin-like growth factor-1 directly affects cardiac cellular remodelling via distinct pathways. IJC Heart and Vasculature, 2021, 36, 100852.	0.6	3
103	Diabetic Nephropathy: Do Cannabinoids Contribute?. Endocrinology, 2012, 153, 1008-1009.	1.4	2
104	The challenges of post-bariatric surgery hypocalcaemia in pre-existing hypoparathyroidism. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	2
105	Sodiumâ€“glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. Medical Journal of Australia, 2021, 214, 94.	0.8	1
106	Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use. Clinical Endocrinology, 2021, , .	1.2	1
107	Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 2022, 24, 350-356.	2.4	1
108	Adrenal gland haemorrhages following motor vehicle accident with resultant adrenal insufficiency. Endocrinology, Diabetes and Metabolism Case Reports, 2022, 2022, .	0.2	1

#	Article	IF	Citations
109	Overnight Counter-Regulatory Hormone Levels and Next Day Glycemia in Adults with Type 1 Diabetes During Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump with Low-Glucose Suspend. Diabetes Technology and Therapeutics, 2017, 19, 438-439.	2.4	0
110	Making sense of newer treatment options for type 2 diabetes. Internal Medicine Journal, 2018, 48, 762-769.	0.5	0
111	The challenges of post-bariatric surgery hypocalcaemia in pre-existing hypoparathyroidism. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	0
112	A system to detect unrecognised diabetes in a tertiary hospital. Diabetic Medicine, 2022, , e14841.	1.2	0